Verici continues to make strong progress in establishing a comprehensive platform for the end-to-end monitoring of organ rejection indicators for patients undergoing kidney transplant surgery. Following the successful validation study data for Tuteva and Clarava, it now has two viable kidney transplant products, with a third one on the way, and is on track to deliver first commercial revenues later this year. Funding is in place until 2024 and we continue to see substantial potential upside as t ....
07 Sep 2022
Interims showcase strong strategic progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interims showcase strong strategic progress
Verici continues to make strong progress in establishing a comprehensive platform for the end-to-end monitoring of organ rejection indicators for patients undergoing kidney transplant surgery. Following the successful validation study data for Tuteva and Clarava, it now has two viable kidney transplant products, with a third one on the way, and is on track to deliver first commercial revenues later this year. Funding is in place until 2024 and we continue to see substantial potential upside as t ....